| 3.365 0.005 (0.15%) | 09-25 15:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.1 | 1-year : | 4.27 |
| Resists | First : | 3.51 | Second : | 3.66 |
| Pivot price | 3.41  |
|||
| Supports | First : | 3.28 | Second : | 2.73 |
| MAs | MA(5) : | 3.37 |
MA(20) : | 3.43 |
| MA(100) : | 3.08  |
MA(250) : | 2.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 28.6 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 5.8 | Low : | 1.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GDRX ] has closed above bottom band by 32.5%. Bollinger Bands are 51.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.42 | 3.42 - 3.43 |
| Low: | 3.27 - 3.29 | 3.29 - 3.3 |
| Close: | 3.33 - 3.36 | 3.36 - 3.39 |
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
Tue, 22 Sep 2026
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Assessing A Potential 18.90% Upside - DirectorsTalk Interviews
Mon, 21 Sep 2026
GoodRx Holdings, Inc. (GDRX) Options Chain - Yahoo Finance - Yahoo! Finance Canada
Wed, 19 Aug 2026
Big GoodRx (NASDAQ: GDRX) backer prepares share sale - Stock Titan
Wed, 05 Aug 2026
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Wed, 05 Aug 2026
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates - Yahoo Finance
Tue, 28 Jul 2026
GoodRx Holdings, Inc. Revenue Breakdown – NASDAQ:GDRX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 107 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 55.9 (%) |
| Shares Short | 5,090 (K) |
| Shares Short P.Month | 6,460 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.89 |
| Profit Margin | 2 % |
| Operating Margin | 11.7 % |
| Return on Assets (ttm) | 3 % |
| Return on Equity (ttm) | 2.5 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 6.65 |
| Sales Per Share | 7.32 |
| EBITDA (p.s.) | 1.01 |
| Qtrly Earnings Growth | -44.5 % |
| Operating Cash Flow | 202 (M) |
| Levered Free Cash Flow | 113 (M) |
| PE Ratio | 56.06 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0.45 |
| Price to Cash Flow | 1.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|